*New* Slator Pro Guide: Scaling an LSP Key Account — Growing Small Clients into Key Accounts
Adelina Lear of contract research organization ICON plc spoke at SlatorCon London on the role of language services and the linguistic validation workflow in clinical trials.
As TransPerfect posts USD 705m in full-year revenues for 2018, CEO Phil Shawe comments on the company’s record setting 2018, his M&A outlook for 2019, neural machine translation, and why Amazon and Google don’t really worry him.
The EU is expected to enact a sweeping overhaul of its regulatory framework for medical devices in early 2017, which includes changes to requirements for multilingual documentation. Brexit also adds to uncertainty.
Two barriers to entry face US medical device companies that want in to China, and the Chinese government has begun to close loopholes; a look at opportunities and expert insights on the medical device market in the world's most populous nation.
Since the start of 2015, China has launched 22 new policies aimed at reforming the regulatory framework for local and international pharma and medical device companies. Sponsored by Lionbridge, Slator’s Shanghai roundtable provided participants a timely update on how policy impacts day-to-day operations
Medical device manufacturers need to keep tight control over content to comply with regulators while staying nimble to get their message across to customers: an exclusive look behind the scenes at how translation is managed at MED-EL, an Austrian manufacturer of hearing implants.
Clinical trials are on the rise in Russia, with a 13% increase in the third quarter of 2015. LSPs active in life sciences would do well to keep watch.
As CROs are increasingly relying on ePRO in clinical trials, the demand for translation and localization of ePRO systems may likewise increase.
Slator Weekly: Join over 15,800 subscribers and get the latest language industry intelligence every Friday
Tool Box: Join 10,000 subscribers for your monthly linguist technology update.
Your information will not be shared with third parties. No Spam.
This will close in 0 seconds